Recent Finacing
Recent Raise
ImpriMed operates a platform that runs live-cell chemosensitivity and immunophenotyping assays on fresh canine and feline blood-cancer samples, uses AI to predict drug responses, and delivers reports to veterinarians.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at ImpriMed.
